The model's full reasoning — Q4 2022 call → NOWe need to determine if management describes an identifiable piece of new business activity that has already started contributing partway through the reported period or is starting right now, and that the reported results captured only a partial early slice, with fuller run-rate arriving over next few quarters as a matter of timing. Let's analyze the transcript. The call is for Q4 and full-year 2022 results. Management discusses several things: HeartBeam AIMI (software) submitted to FDA, expecting clearance in Q2, limited market release in early Q3. HeartBeam AIMIGo (device) - they plan to file V1 submission shortly, V2 submission targeted for Q4. They acquired LIVMOR assets, including Halo+ AFib detection system. They partnered with Evolve Manufacturing for AIMIGo. They have patents. Key question: Is there a new business activity that has already started contributing partway through the reported period? The reported period is Q4 2022 and full year 2022. What started contributing? The LIVMOR acquisition? They acquired substantially all assets from LIVMOR. When did that close? The transcript says "Recently, we announced the acquisition of substantially all assets from LIVMOR" - but no specific date. They also mention "our newly acquired, state-of-the-art, FDA cleared, watch-based arrythmia detection tool" - but is it contributing revenue? They don't mention any revenue from it. They talk about integrating it with AIMIGo later. So it's not contributing yet. What about AIMI? It's submitted to FDA, not cleared yet. So no revenue. AIMIGo? Not yet submitted, just planning. So there is no product that is already live and generating revenue. The company is pre-revenue. They have no sales. They are developing products and awaiting FDA clearances. The question asks: "does management describe an identifiable piece of new business activity that has ALREADY STARTED CONTRIBUTING PARTWAY THROUGH THE REPORTED PERIOD OR IS STARTING RIGHT NOW" - meaning it's already contributing to revenue or activity. But the company has no revenue. They are a development stage company. They mention costs, R&D, etc. But no revenue. The only possible thing is the LIVMOR acquisition, but they say it's an acquisition of assets, and they plan to integrate it. They don't say it's contributing revenue. They also mention "we have acquired the whole technical team" - but that's not revenue.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| GPRE | Green Plains Inc. | Q4 2023 | 2024-02-07 | F |
| TEL | TE Connectivity Ltd. | Q4 2023 | 2023-11-01 | B |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| WHF | WhiteHorse Finance | Q1 2022 | 2022-05-10 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| MAS | Masco Corporation | Q3 2018 | 2018-10-30 | C |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| ACHC | Acadia Healthcare Company, Inc. | Q4 2017 | 2018-02-22 | C+ |
| HTLF | Heartland Financial USA, Inc. | Q3 2017 | 2017-10-30 | B+ |
| MXL | MaxLinear, Inc. | Q2 2017 | 2017-08-08 | C |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| LEA | Lear Corporation | Q2 2017 | 2017-07-26 | B+ |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
| SHOO | Steven Madden, Ltd. | Q1 2017 | 2017-04-21 | C |
| PDCO | Patterson Companies, Inc. | Q3 2017 | 2017-02-23 | C |
| WTS | Watts Water Technologies, Inc. | Q4 2016 | 2017-02-10 | B |
SHOO · Q1 2017 → YESThe question is about whether management describes a new business activity that has already started contributing partway through the reported period or is starting now, and that the reported results o...YES The transcript describes the Schwartz & Benjamin acquisition as a new contributor that began delivering sales in the reported Q1 period ($14 million, slightly above plan), with the results capturing only its early partial slice. Management explicitly notes that the full-quarter impact will arrive in subsequent quarters (dragging gross margin more going forward), 2017 will be breakeven-to-EPS, and meaningful profit contribution starts in 2018—making the fuller run-rate a pure timing matter of integration and ramp rather than any further winning. This meets all three criteria. (Madden NYC and SM Europe are also new launches/JVs with early/modest contributions and growth ahead, but Schwartz & Benjamin is the clearest fit for the exact timing story.) NO for the other items because they are either not yet live (China JV), not described as partial/early-slice (SM Europe international growth), or not framed as timing-driven ramp (Madden NYC modest contribution is positive but 2018+ profit is more about execution than pure timing). The answer is YES.
AFL · Q2 2023 → YESThe question is about whether management describes a new business activity that has already started contributing partway through the reported period or is starting now, and that the reported results o...YES The transcript describes the WINGS cancer insurance product launch in Japan Post (early April, during Q2) as a new, nameable contributor that began transacting mid-period. Management explicitly states it was the "majority contributor" to the 60% cancer sales increase in Q2 versus 2022, 26.6% overall sales premium growth, and notes the reported results captured only an early slice because "right when you launch the product, you'll have an immediate jump in sales in the early months followed by a calming down" with "still much more runway...
PDCO · Q3 2017 → YESThe question is about whether management describes a new business activity that has already started contributing partway through the reported period or is starting now, and that the reported results o...YES The transcript describes Heartland Dental as a new customer relationship that began contributing in January (during the reported Q3 period), with the rollout completed on schedule and the business now "getting close to being fully operational." Management explicitly notes that this was "not a significant contributor to consumable sales in the third quarter" — confirming the reported results captured only a partial, early slice — while highlighting the "outstanding start" and excitement for further growth as the relationship scales.